Menu
Curie Logo
Donate
  • Home

Clinical trials

Essais cliniques
Search for a clinical trial
Filter

195 result(s)

  • Cancers gynécologiques
    Paris
    GLORIOSA
    Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA).

    MANUEL RODRIGUES

  • Cancers gynécologiques
    Saint-Cloud
    AFTERGYN
    Optimize the Support of Patients in Pelvic Onco-gynecology Through Adapted Support Care in the Post-cancer Period. AFTERGYN Pilot Phase (AFTERGYN)

    DIANA BELLO ROUFAI

  • Cancers urogénitaux
    Paris, Saint-Cloud
    CAAA617D12302
    A prospective, multicenter, open-label, randomized international Phase III study evaluating treatment with lutetium (177Lu) vipivotide tetraxetan (AAA617) versus surveillance alone to delay the need for castration or disease recurrence in adult male patients with PSMA-positive oligometastatic prostate cancer.

    CAPUCINE RICHARD

  • Paris
    DF1001-001
    A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

    EMANUELA ROMANO

  • Paris
    MCLA-158-CL01
    Phase 1 Dose Finding Study Evaluating the Bispecific Antibody MCLA-158 in Metastatic Colorectal Cancer and Other Advanced Solid Tumors.

    EDITH BORCOMAN

  • Myélome
    Saint-Cloud
    R5458-ONC-2245
    An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; anti-;BCMA x anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab,;Pomalidomide, and Dexamethasone (EPd), in Patients with Relapsed/Refractory;Multiple Myeloma (LINKER-MM3).

    Cyrine ELLOUZ

  • Lung cancer
    Paris
    DS1062-A-U303/ TROPION-Lung07
    A Randomized Phase 3 Study of Datopotamab Deruxtecan;(Dato-DXd) and Pembrolizumab, with or Without Platinum;Chemotherapy, in Subjects with No Prior Therapy for;Advanced or Metastatic PD-L1 TPS <50% Non-squamous;Non-small Cell Lung Cancer Without Actionable Genomic;Alterations;(TROPION-Lung07)

    NICOLAS GIRARD

  • Cancers gynécologiques
    Saint-Cloud
    DS6000-109
    A Phase 2/3, Multicenter, Randomized Study of Raludotatug;Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate,;in Subjects with Platinum-resistant, High-grade Ovarian, Primary;Peritoneal, or Fallopian Tube Cancer.

    DIANA BELLO ROUFAI

  • Eye tumors / Uveal melanoma
    Paris
    IDE 196-002
    IDE196 (Darovasertib) in Combination with Crizotinib Versus Investigator·s Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2).

    SOPHIE PIPERNO-NEUMANN

  • Cancers gynécologiques
    Paris
    VS-6766-301 (RAMP 301)
    A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus;InvestigatorÀs Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC).

    MANUEL RODRIGUES

  • Paris, Saint-Cloud
    POP-ART
    A Phase I Study on Tuvusertib (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients;with advanced solid tumors.

    FRANCOIS-CLEMENT BIDARD

  • Breast cancer
    Paris
    BGB-43395-101
    Phase Ia/Ib study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the CDK4 inhibitor BGB-43395 as monotherapy and in combination with other treatments in patients with HR+/HER2- metastatic breast cancer and other advanced solid tumors.

    MARIE PAULE SABLIN

  • Cancers gynécologiques
    Saint-Cloud
    E7386-J081-102_(PENT-02)
    An Open-Label Study of E7386 in Combination With Other;Anticancer Drug(s) in Subjects With Solid Tumors.

    DIANA BELLO ROUFAI

  • Paris
    GSK 219451 - POPSTAR
    Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination with Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR).

    AMAURY LERUSTE

  • Saint-Cloud
    MK 2140-010
    A Randomized, Open-label, Multisite, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP versus R-CHOP in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) (waveLINE-010).

    CLEMENTINE SARKOZY

  • Paris, Saint-Cloud
    REVCCI
    Use of Virtual Reality Mask or Music Therapy for Analgesia and Anxiolytic Purpose When Totally Implanted Venous Access Device (IVAD) for Chemotherapy Under Local Anesthesia

    ABDELMALEK GHIMOUZ

  • Sarcomas
    Paris
    TANGENT (SNX-301-020)
    A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Tenosynovial Giant Cell Tumour.

    SOPHIE PIPERNO-NEUMANN

  • Breast cancer
    Paris, Saint-Cloud
    Treat ctDNA
    Elacestrant for Treating ER+/·HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) (TREAT ctDNA)

    FRANCOIS-CLEMENT BIDARD, ETIENNE BRAIN

  • Breast cancer
    Paris, Saint-Cloud
    CAPPA
    Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery (CAPPA).

    DELPHINE LOIRAT

  • Lung cancer
    Paris
    R2810-ONC-2268
    A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE;CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS;CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE;PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE;NON-SMALL CELL LUNG CANCER;SUBPROTOCOL 1: REGN7075

    NICOLAS GIRARD

  • Tumeurs du système nerveux central
    Paris, Saint-Cloud
    COG-PROTON-01
    Long-term cognitive and functional impact of proton-therapy or modern fractionated radiotherapy in cavernous sinus meningioma: An open-label randomized 1:1 phase III study

    EMMANUEL JOUGLAR, MAXIME LOO

  • ENT/Head and Neck Cancers
    Paris
    MCLA-158-CL03/LiGeR-HN1
    A phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

    CHRISTOPHE LE TOURNEAU

  • Cancer de l'ovaire
    Paris, Saint-Cloud
    SALVOVAR
    A pragmatic randomized phase III trial to assess the utility of adjusting;chemotherapy dose & dosing schedule with the SALVage weekly dose-dense;regimen in patients with poor prognostic OVARian cancers based on the tumor;unfavorable primary chemosensitivity and incomplete debulking surgery.

    CLEMENT BONNET

  • Paris
    DF6215-001
    A Phase 1/1b, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors

    EMANUELA ROMANO

  • Lung cancer
    Paris
    MK-2870-004
    A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy;(Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous;Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations.

    CATHERINE DANIEL

  • Lung cancer
    Paris
    BAYER 22615 (SOHO 02)
    A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations.

    NICOLAS GIRARD

  • Eye tumors / Uveal melanoma
    Paris
    ATOM
    Adjuvant tebentafusp (IMCgp100) versus observation in HLA-A*02:01positive patients following definitive treatment of high-risk uveal melanoma: an EORTC randomized phase III study;(ATOM Trial)

    MANUEL RODRIGUES

  • Lymphoma
    Saint-Cloud
    CA073-1020
    A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

    CLEMENTINE SARKOZY

  • Paris
    EUonQoL
    Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe · Developing the toolkit: Patient preferences and priorities for quality of life domains across the cancer care continuum.

  • Lung cancer
    Paris
    HARMONi-3
    A randomized, controlled, multiregional Phase 3 study of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancer.

    PAULINE DU RUSQUEC

<
1 ...7
>